PE20081679A1 - Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso - Google Patents

Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso

Info

Publication number
PE20081679A1
PE20081679A1 PE2007001726A PE2007001726A PE20081679A1 PE 20081679 A1 PE20081679 A1 PE 20081679A1 PE 2007001726 A PE2007001726 A PE 2007001726A PE 2007001726 A PE2007001726 A PE 2007001726A PE 20081679 A1 PE20081679 A1 PE 20081679A1
Authority
PE
Peru
Prior art keywords
aril
alkyl
phosphoinositide
methods
kinase inhibitor
Prior art date
Application number
PE2007001726A
Other languages
English (en)
Spanish (es)
Inventor
Tracy Bayliss
Irina Chuckowree
Adrian FOLKES
Sally Jane Oxenford
Nan Chi Wan
Georgette Castanedo
Richard Goldsmith
Janet Gunzner
Tim Heffron
Simon Mathieu
Alan Olivero
Daniel P Sutherlin
Bing-Yan Zhu
Steven Staben
Original Assignee
Hoffmann La Roche
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39188533&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081679(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche, Genentech Inc filed Critical Hoffmann La Roche
Publication of PE20081679A1 publication Critical patent/PE20081679A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
PE2007001726A 2006-12-07 2007-12-05 Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso PE20081679A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87344806P 2006-12-07 2006-12-07
US97725707P 2007-10-03 2007-10-03

Publications (1)

Publication Number Publication Date
PE20081679A1 true PE20081679A1 (es) 2008-12-18

Family

ID=39188533

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001726A PE20081679A1 (es) 2006-12-07 2007-12-05 Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso

Country Status (22)

Country Link
US (3) US7888352B2 (en:Method)
EP (2) EP2518074B1 (en:Method)
JP (1) JP5284977B2 (en:Method)
KR (1) KR101460816B1 (en:Method)
AR (1) AR064155A1 (en:Method)
AU (1) AU2007329352B2 (en:Method)
BR (1) BRPI0717923A2 (en:Method)
CA (1) CA2671782C (en:Method)
CL (1) CL2007003520A1 (en:Method)
CO (1) CO6190615A2 (en:Method)
CR (1) CR10915A (en:Method)
EC (1) ECSP099496A (en:Method)
ES (1) ES2544082T3 (en:Method)
MA (1) MA31146B1 (en:Method)
MX (1) MX2009005950A (en:Method)
MY (1) MY180595A (en:Method)
NO (1) NO20092566L (en:Method)
NZ (1) NZ578162A (en:Method)
PE (1) PE20081679A1 (en:Method)
RU (1) RU2468027C2 (en:Method)
TW (1) TWI499420B (en:Method)
WO (1) WO2008070740A1 (en:Method)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69636466T2 (de) * 1996-09-04 2007-08-09 Intertrust Technologies Corp., Sunnyvale Treuhand infrastruktur unterstützungssysteme, verfahren und techniken zum sicheren elektronischen handel, elektronische transaktionen, steuerung und automatisierung von handelsverfahren, verteilte datenverarbeitung und verwalten von rechten
CA2650290C (en) * 2006-04-26 2015-11-17 Genentech, Inc. Pharmaceutical compounds
MY180595A (en) 2006-12-07 2020-12-03 Genentech Inc Phosphoinositide 3-kinase inhibitor compounds and methods of use
RU2470936C2 (ru) 2006-12-07 2012-12-27 Дженентек, Инк. Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения
JP5539190B2 (ja) * 2007-06-12 2014-07-02 エフ．ホフマン−ラ ロシュ アーゲー チアゾロピリミジン類及びホスファチジルイノシトール−３キナーゼのインヒビターとしてのそれらの使用
KR101584823B1 (ko) * 2007-09-12 2016-01-22 제넨테크, 인크. 포스포이노시타이드 3-키나제 저해제 화합물과 화학치료제의 배합물 및 이의 사용방법
CN101932587A (zh) * 2007-09-24 2010-12-29 吉宁特有限公司 噻唑并嘧啶pi3k抑制剂化合物及使用方法
CN101909631B (zh) * 2007-10-25 2012-09-12 健泰科生物技术公司 制备噻吩并嘧啶化合物的方法
GB0721095D0 (en) * 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
CL2008003798A1 (es) 2007-12-19 2009-10-09 Amgen Inc Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
JP5421925B2 (ja) 2007-12-19 2014-02-19 ジェネンテック， インコーポレイテッド ５−アニリノイミダゾピリジン及び使用の方法
ES2387707T3 (es) 2007-12-21 2012-09-28 Genentech, Inc. Azaindolizinas y procedimientos de uso
NZ621433A (en) 2008-03-18 2015-10-30 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
NZ590777A (en) * 2008-07-31 2012-11-30 Genentech Inc PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE FOR INHIBITING mTOR
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
WO2010043000A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators and their use thereof
AU2009304596A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1P receptors modulators
AU2010203512C1 (en) 2009-01-08 2013-10-17 Curis, Inc. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
CA2753285A1 (en) 2009-03-12 2010-09-16 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
EP2411398B1 (en) 2009-03-24 2014-12-17 Sumitomo Chemical Company, Limited Method for manufacturing a boronic acid ester compound
SG175708A1 (en) 2009-05-27 2011-12-29 Genentech Inc Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
US8158625B2 (en) * 2009-05-27 2012-04-17 Genentech, Inc. Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
CN102480961A (zh) * 2009-06-24 2012-05-30 健泰科生物技术公司 与含氧杂环稠合的嘧啶化合物、组合物和使用方法
CN102625807B (zh) * 2009-09-08 2016-03-09 霍夫曼-拉罗奇有限公司 4-取代的吡啶-3-基-甲酰胺化合物和使用方法
WO2011036284A1 (en) 2009-09-28 2011-03-31 F. Hoffmann-La Roche Ag Benzoxepin pi3k inhibitor compounds and methods of use
KR101489045B1 (ko) * 2009-10-12 2015-02-02 에프. 호프만-라 로슈 아게 Ｐｉ3ｋ 억제자 및 ｍｅｋ 억제자의 조합
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
CA2779574C (en) 2009-11-05 2018-12-18 Rhizen Pharmaceuticals S.A. Novel kinase modulators
JP5572715B2 (ja) * 2009-11-12 2014-08-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｎ−７置換プリン及びピラゾロピリミジン化合物、組成物及び使用方法
ES2596654T3 (es) * 2009-11-12 2017-01-11 F. Hoffmann-La Roche Ag Compuestos de purina N-9-sustituida, composiciones y métodos de uso
BR112012019635A2 (pt) 2010-02-22 2016-05-03 Hoffmann La Roche compostos inibidores de pirido[3,2-d] pirimidina pi3k delta e métodos de uso
JP2013523678A (ja) 2010-03-30 2013-06-17 ノバルティス アーゲー 慢性的に活性なｂ細胞受容体シグナル伝達を有するｂ細胞リンパ腫の治療用のｐｋｃ阻害薬
JP5555378B2 (ja) 2010-07-14 2014-07-23 エフ．ホフマン−ラ ロシュ アーゲー Ｐｉ３ｋｐ１１０デルタに選択的なプリン化合物とその使用の方法
NZ609448A (en) 2010-12-16 2015-07-31 Hoffmann La Roche Tricyclic pi3k inhibitor compounds and methods of use
KR20130116358A (ko) 2011-02-09 2013-10-23 에프. 호프만-라 로슈 아게 Pi3 키나아제 억제제로서 헤테로사이클릭 화합물
CN103562210B (zh) 2011-03-21 2016-05-25 弗·哈夫曼-拉罗切有限公司 对pI3K 110δ具有选择性的苯并氧氮杂*化合物及使用方法
SG10201602569RA (en) 2011-04-01 2016-05-30 Curis Inc Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
AP4075A (en) 2011-05-04 2017-03-23 Rhizen Pharmaceuticals S A Novel compounds as modulators of protein kinases
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
CA2835760A1 (en) 2011-06-03 2012-12-06 F. Hoffmann-La Roche Ag Methods of treating mesothelioma with a pi3k inhibitor compound
BR112014008241A2 (pt) * 2011-10-07 2017-04-18 Cellzome Ltd composto, composição farmacêutica, métodos para tratar, controlar, retardar ou prevenir doenças e distúrbios, e para preparar um composto, e, uso de um composto
KR20160027219A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
CN103450204B (zh) * 2012-05-31 2016-08-17 中国科学院上海药物研究所 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
KR101915942B1 (ko) 2012-06-08 2018-11-06 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
DK3260455T3 (da) 2012-07-04 2019-06-11 Rhizen Pharmaceuticals S A Selektive pi3k delta-hæmmere
US9145411B2 (en) 2012-08-02 2015-09-29 Asana Biosciences, Llc Substituted amino-pyrimidine derivatives
RU2680096C2 (ru) 2012-08-21 2019-02-15 ОПКО ФАРМАСЬЮТИКАЛС, Эл Эл Си Липосомальные препараты
KR101697444B1 (ko) 2012-08-30 2017-01-17 에프. 호프만-라 로슈 아게 다이옥시노- 및 옥사진-[2,3-d]피리미딘 pi3k 억제제 화합물 및 사용 방법
KR101698283B1 (ko) * 2012-10-10 2017-01-19 에프. 호프만-라 로슈 아게 티에노피리미딘 화합물의 제조 방법
WO2014068070A1 (en) 2012-10-31 2014-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
MX361673B (es) * 2013-05-06 2018-12-11 Hoffmann La Roche Procedimiento para la preparación de intermediarios de ácido borónico.
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
CN105985354B (zh) * 2015-02-09 2020-10-02 南京盖特医药技术有限公司 嘧啶衍生物、细胞毒性剂、药物组合物及其应用
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
EP3314265B1 (en) 2015-06-29 2019-07-24 H. Hoffnabb-La Roche Ag Methods of treatment with taselisib
CA2982708C (en) * 2015-07-02 2023-10-03 F. Hoffmann-La Roche Ag Benzoxazepin oxazolidinone compounds and methods of use
EP3317283B1 (en) * 2015-07-02 2019-04-03 H. Hoffnabb-La Roche Ag Benzoxazepin oxazolidinone compounds and methods of use
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018085342A1 (en) * 2016-11-02 2018-05-11 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
SG11201906223TA (en) 2016-12-22 2019-08-27 Amgen Inc Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
US11459306B2 (en) 2017-07-31 2022-10-04 The Trustees Of Columbia University In The City Of New York Compounds, compositions, and methods for treating T-cell acute lymphoblastic leukemia
UY37870A (es) 2017-09-08 2019-03-29 Amgen Inc Inhibidores de kras g12c y métodos para utilizarlos campo de la invención
US11613549B2 (en) 2018-01-23 2023-03-28 Basf Se Bromination of pyridine derivatives
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
WO2019199864A1 (en) 2018-04-10 2019-10-17 Neuropore Therapies, Inc. Tri-substituted aryl and heteroaryl derivatives as modulators of pi3-kinase and autophagy pathways
CA3095512A1 (en) * 2018-04-10 2019-10-17 Neuropore Therapies, Inc. Morpholine derivates as inhibitors of vps34
CA3099118A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
MA52501A (fr) 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
MX2020011907A (es) 2018-05-10 2021-01-29 Amgen Inc Inhibidores de kras g12c para el tratamiento de cancer.
AU2019278998B2 (en) 2018-06-01 2023-11-09 Amgen Inc. KRAS G12C inhibitors and methods of using the same
JP7357644B2 (ja) 2018-06-11 2023-10-06 アムジエン・インコーポレーテツド がんを処置するためのｋｒａｓ ｇ１２ｃ阻害剤
AU2019336588B2 (en) 2018-06-12 2022-07-28 Amgen Inc. KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
SI3813946T1 (sl) 2018-06-15 2024-07-31 Janssen Pharmaceutica Nv Analogi rapamicina in njihove uporabe
MA53619A (fr) 2018-09-11 2021-12-15 Curis Inc Polythérapie avec un inhibiteur de phosphoinositide 3-kinase ayant une fraction de liaison au zinc
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
WO2020106640A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
WO2020103897A1 (zh) * 2018-11-22 2020-05-28 上海迪诺医药科技有限公司 杂环稠合嘧啶衍生物、其药物组合物及应用
JOP20210154B1 (ar) 2018-12-20 2023-09-17 Amgen Inc مثبطات kif18a
ES2996960T3 (en) 2018-12-20 2025-02-13 Amgen Inc Heteroaryl amides useful as kif18a inhibitors
EP3897855B1 (en) 2018-12-20 2023-06-07 Amgen Inc. Kif18a inhibitors
US12441736B2 (en) 2018-12-20 2025-10-14 Amgen Inc. KIF18A inhibitors
SG11202106635WA (en) 2018-12-21 2021-07-29 Daiichi Sankyo Co Ltd Combination of antibody-drug conjugate and kinase inhibitor
US20230148450A9 (en) 2019-03-01 2023-05-11 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
WO2020180770A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
CR20210665A (es) 2019-05-21 2022-01-25 Amgen Inc Formas en estado sólido
CN114302880B (zh) 2019-08-02 2025-07-15 美国安进公司 Kif18a抑制剂
US20220281843A1 (en) 2019-08-02 2022-09-08 Amgen Inc. Kif18a inhibitors
WO2021026099A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
CN114391012B (zh) 2019-08-02 2025-10-31 美国安进公司 作为kif18a抑制剂的吡啶衍生物
US20240139193A1 (en) 2019-10-15 2024-05-02 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
EP4684786A2 (en) 2019-10-24 2026-01-28 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
CA3160142A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
CN120988055A (zh) 2019-11-04 2025-11-21 锐新医药公司 Ras抑制剂
US11739074B2 (en) 2019-11-04 2023-08-29 Revolution Medicines, Inc. Ras inhibitors
JP7812056B2 (ja) 2019-11-08 2026-02-09 レヴォリューション・メディスンズ，インコーポレイテッド 二環式ヘテロアリール化合物及びその使用
TWI882037B (zh) 2019-11-14 2025-05-01 美商安進公司 Kras g12c抑制劑化合物之改善的合成
AU2020383535A1 (en) 2019-11-14 2022-05-05 Amgen Inc. Improved synthesis of KRAS G12C inhibitor compound
CN114980976A (zh) 2019-11-27 2022-08-30 锐新医药公司 共价ras抑制剂及其用途
BR112022010754A2 (pt) 2019-12-05 2022-08-23 Anakuria Therapeutics Inc Análogos de rapamicina e usos dos mesmos
WO2021126816A1 (en) 2019-12-16 2021-06-24 Amgen Inc. Dosing regimen of a kras g12c inhibitor
BR112022010086A2 (pt) 2020-01-07 2022-09-06 Revolution Medicines Inc Dosagem do inibidor de shp2 e métodos de tratamento de câncer
TW202214253A (zh) 2020-06-18 2022-04-16 美商銳新醫藥公司 延遲、預防及治療對ｒａｓ抑制劑之後天抗性之方法
AU2021344830A1 (en) 2020-09-03 2023-04-06 Revolution Medicines, Inc. Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
MX2023003060A (es) 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
EP4267250A1 (en) 2020-12-22 2023-11-01 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
TW202309053A (zh) 2021-05-05 2023-03-01 美商銳新醫藥公司 Ｒａｓ抑制劑
IL308193A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors
EP4412617A4 (en) * 2021-10-07 2025-12-24 Tme Therapeutics Llc NEW PIKFYVE INHIBITORS AND THEIR METHODS OF USE
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
US20250282782A1 (en) 2021-12-17 2025-09-11 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4490146B1 (en) 2022-03-07 2026-02-18 Amgen Inc. A process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
JP2025521232A (ja) 2022-06-10 2025-07-08 レボリューション メディシンズ インコーポレイテッド 大環状ｒａｓ阻害剤
GEAP202516749A (en) 2022-10-14 2025-07-25 Black Diamond Therapeutics Inc Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
EP4687905A1 (en) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
EP4688790A1 (en) 2023-04-07 2026-02-11 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
KR20250169290A (ko) 2023-04-14 2025-12-02 레볼루션 메디슨즈, 인크. Ras 억제제의 결정형, 이를 함유하는 조성물 및 이의 사용 방법
KR20250172857A (ko) 2023-04-14 2025-12-09 레볼루션 메디슨즈, 인크. Ras 억제제의 결정형
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE754606A (fr) 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE1959403A1 (de) 1969-11-26 1971-06-03 Thomae Gmbh Dr K Neue 2-(5-Nitro-2-furyl)-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
DE2050814A1 (de) 1970-10-16 1972-04-20 Dr. Karl Thomae Gmbh, 7950 Biberach Neue Verfahren zur Herstellung von 2-(5-Nitro-2-furyl)-thieno eckige Klammer auf 3,2-d eckige Klammer zu pyrimidinen
BE759493A (fr) 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
US3763156A (en) 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
RO62428A (fr) 1971-05-04 1978-01-15 Thomae Gmbh Dr K Procede pour la preparation des thyeno-(3,2-d)-pyrimidines
CH592668A5 (en:Method) 1973-10-02 1977-10-31 Delalande Sa
GB1570494A (en) 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
ZA782648B (en) 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
US5075305A (en) 1991-03-18 1991-12-24 Warner-Lambert Company Compound, composition and use
AU3262593A (en) 1992-01-11 1993-08-03 Schering Agrochemicals Limited Biheterocyclic fungicidal compounds
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US5679683A (en) * 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JPH08175990A (ja) 1994-12-19 1996-07-09 Mitsubishi Chem Corp Ｐｉ３キナーゼ阻害剤とその製造法
JPH08176070A (ja) 1994-12-19 1996-07-09 Mitsubishi Chem Corp ジデプシド誘導体及びｐｉ３キナーゼ阻害剤
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
GB9521987D0 (en) 1995-10-26 1996-01-03 Ludwig Inst Cancer Res Phosphoinositide 3-kinase modulators
AUPO903897A0 (en) 1997-09-08 1997-10-02 Commonwealth Scientific And Industrial Research Organisation Organic boronic acid derivatives
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
KR100446363B1 (ko) 1997-11-11 2004-09-01 화이자 프로덕츠 인코포레이티드 항암제로 유용한 티에노피리미딘 및 티에노피리딘 유도체
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
JP2001247477A (ja) 2000-03-03 2001-09-11 Teikoku Hormone Mfg Co Ltd 抗腫瘍剤
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
CN1186324C (zh) 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
ES2236481T3 (es) 2001-01-16 2005-07-16 Glaxo Group Limited Combinacion farmaceutica que contiene una 4-quinazolinamina y paclitaxel, carboplatino o vinorelbina para el tratamiento de cancer.
EP1417976A4 (en) 2001-07-26 2004-09-15 Santen Pharmaceutical Co Ltd AGENT FOR TREATING GLAUKOM WITH A COMPOUND WITH PI3-KINASE INHIBITING EFFECT
US6703414B2 (en) 2001-09-14 2004-03-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Device and method for treating restenosis
DE10148883A1 (de) * 2001-10-04 2003-04-10 Merck Patent Gmbh Pyrimidinderivate
AU2002357667A1 (en) 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
AU2002349912A1 (en) 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
WO2003037886A2 (en) 2001-10-30 2003-05-08 Pharmacia Corporation Heteroaromatic carboxamide derivatives for the treatment of inflammation
EP1531813A1 (en) 2002-07-10 2005-05-25 Applied Research Systems ARS Holding N.V. Use of compounds for increasing spermatozoa motility
RS115904A (sr) 2002-07-10 2006-12-15 Applied Research Systems Ars Holding N.V. Derivati benzena fuzionisani sa azolidinon vinilom
US20040092561A1 (en) 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
ES2217956B1 (es) 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
WO2006040966A1 (ja) 2004-10-08 2006-04-20 Astellas Pharma Inc. 芳香環縮合ピリミジン誘導体
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US8252792B2 (en) 2006-04-26 2012-08-28 F. Hoffman-La Roche Ag Pyrimidine derivatives as PI3K inhibitors
PT2024372E (pt) 2006-04-26 2010-09-16 Hoffmann La Roche Derivado de tieno[3,2-d]pirimidina útil como inibidor de pi3k
CA2650290C (en) 2006-04-26 2015-11-17 Genentech, Inc. Pharmaceutical compounds
EP2046799B1 (en) 2006-04-26 2017-07-19 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
GB0608820D0 (en) 2006-05-04 2006-06-14 Piramed Ltd Pharmaceutical compounds
MY180595A (en) * 2006-12-07 2020-12-03 Genentech Inc Phosphoinositide 3-kinase inhibitor compounds and methods of use
RU2470936C2 (ru) 2006-12-07 2012-12-27 Дженентек, Инк. Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения

Also Published As

Publication number Publication date
CA2671782A1 (en) 2008-06-12
US20130129820A1 (en) 2013-05-23
NO20092566L (no) 2009-09-07
CA2671782C (en) 2017-01-10
JP2010512338A (ja) 2010-04-22
WO2008070740A1 (en) 2008-06-12
RU2468027C2 (ru) 2012-11-27
EP2518074B1 (en) 2015-07-22
ES2544082T3 (es) 2015-08-27
AU2007329352A1 (en) 2008-06-12
JP5284977B2 (ja) 2013-09-11
BRPI0717923A2 (pt) 2013-10-22
KR101460816B1 (ko) 2014-11-12
MY180595A (en) 2020-12-03
NZ578162A (en) 2011-12-22
TWI499420B (zh) 2015-09-11
US8383620B2 (en) 2013-02-26
US7888352B2 (en) 2011-02-15
TW200829253A (en) 2008-07-16
US20080242665A1 (en) 2008-10-02
EP2518074A1 (en) 2012-10-31
MX2009005950A (es) 2009-10-12
KR20090108016A (ko) 2009-10-14
US8993563B2 (en) 2015-03-31
CR10915A (es) 2009-08-31
CO6190615A2 (es) 2010-08-19
CL2007003520A1 (es) 2008-08-22
US20110097349A1 (en) 2011-04-28
AU2007329352B2 (en) 2013-01-17
ECSP099496A (es) 2009-09-29
AR064155A1 (es) 2009-03-18
RU2009125897A (ru) 2011-01-20
MA31146B1 (fr) 2010-02-01
EP2114949A1 (en) 2009-11-11

Similar Documents

Publication Publication Date Title
PE20081679A1 (es) Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso
PE20060215A1 (es) 4-fenilamino-quinazolin-6-il-amidas
PE20081783A1 (es) Nuevas 2-aminooxazolinas como ligandos de taar1
PE20061436A1 (es) Derivados de amida sustituida como inhibidores de proteina quinasa
BR122012009489B8 (pt) processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso
PE20090952A1 (es) Compuestos de pirazol moduladores de raf
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
DE602005016775D1 (de) Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion
PE20091621A1 (es) Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen
DOP2010000194A (es) Derivados de oxadiazol activos sobre fosfato de esfingosina-1
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE20141681A1 (es) Inhibidores de btk
PT1289955E (pt) Piperidinas para utilizacao como antagonistas dos receptores da orexina
PE20080830A1 (es) Compuestos derivados de sulfonilo que modulan el receptor cb2
PE20140868A1 (es) Antagonistas trpm8 y su uso en tratamientos
ATE431345T1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
ATE487715T1 (de) Triazolderivate als modulatoren von dopamin-d3- rezeptoren
PE20041080A1 (es) Preparacion de medicamentos derivados de indolina sustituidos con heterociclos
PE20090592A1 (es) Nuevos derivados de piperazina-amida
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
PE20020603A1 (es) Derivados de pirimidina como antagonista del receptor del neuropeptido y (npy)
PE20030718A1 (es) Lactamas como antagonistas de taquiquininas
DK1765816T3 (da) Substituerede 1-propinylpiperaziner med affinitet for MGluR5-receptoren til behandling af smertetilstande
HRP20050628A2 (en) Substituted benzoyl derivatives uses as herbicides
ATE493404T1 (de) Azabicyclo-(3,1,0)-hexan-derivate als modulatoren von dopamin-d3-rezeptoren

Legal Events

Date Code Title Description
FG Grant, registration